Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today ...

Formulators of parenteral drugs must be cautious of specific considerations and challenges that arise during development and manufacture. As the numbers of poorly soluble and complex molecules, such ...

Insights into molecular behaviors and predictive capabilities are bringing numerous benefits. The potential benefits afforded by molecular modeling when applied to formulation development are, in fact ...

According to Theratechnologies, Egrifta WR is set to replace Egrifta SV. The Food and Drug Administration (FDA) has approved Egrifta WR ™, a new concentrated formulation (F8) of tesamorelin, for the ...

The success of the mRNA vaccines for COVID-19 led to explosive growth in lipid nanoparticle (LNP)-mediated drug delivery for RNA vaccines and therapeutics. As these projects scale into clinical trials ...

Lipid nanoparticle formulation has increased over the past two decades. LNPs have proven to be effective nano-based delivery vehicles for cytotoxic chemotherapeutic drugs, nucleic acid therapies and ...